Patients Undergoing Gastrointestinal Endoscopy Clinical Trial
Official title:
Phase Ⅲ Placebo-controlled Study of NPO-11 in Chinese Patients Undergoing Gastrointestinal Endoscopy
Chinese patients who require gastrointestinal endoscopy will receive an intra-gastric single
dose of NPO-11 20ml. The superiority of NPO-11 compared to placebo as a premedication for
endoscopy will be verified in a randomized, double-blind, parallel-assignment design based on
the proportion of patients having no gastric peristalsis.
The safety of NPO-11 will be evaluated based on adverse events and adverse drug reactions
observed between informed consent and 7 days after administration in comparison with the
placebo group.
n/a